Maxillary Sinusitis Clinical Trial
— SPEEDOfficial title:
Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial Eradication and Key Symptom Relief in the Treatment of Acute Bacterial Maxillary Sinusitis With Moxifloxacin 400 mg QD
This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.
Status | Completed |
Enrollment | 192 |
Est. completion date | January 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of acute sinusitis with signs and symptoms present for >7 days but < 28 days as defined by A), radiographic, and B) clinical criteria, as follows:a. The presence of 1 or more of the following on a radiographic paranasal sinus film (Waters' view) or limited CT scan:** evidence of air-fluid levels** opacification. The presence of at least one major and one minor symptom as defined in the list below:** Major Symptoms*** Purulent anterior or posterior nasal discharge*** Unilateral moderate or severe facial pain or malar tenderness** Minor Symptoms*** Cough or frequent throat clearing*** Frontal headache*** Halitosis*** Fever (oral > 38.0°C/100.4°F, tympanic > 38.5°C/101.2°F)*** Purulent secretions obtained via middle meatus secretion sampling using nasal endoscopic technique; the specimen sent for Gram stain, culture and susceptibility testing prior to initiation of antimicrobial therapy Exclusion Criteria: - History of chronic sinusitis defined as greater than four weeks of continuous symptoms (patients with history of sinus surgery may be included; patients with recurrent sinusitis may be included) - Known bacteremia, meningitis or infection infiltrating the tissues neighboring the sinuses- Received systemic antibacterial therapy likely to be effective in sinusitis for more than 24 hours within 7 days of enrollment- A requirement for concomitant systemic antibacterial therapy with agents other than those specified in this protocol- Known immunodeficiency diseases including AIDS (CD4 <200)- On topical nasal or systemic corticosteroids, unless they have been on a stable dose for > 4 weeks prior to enrollment- History of allergy to quinolone antibiotics or related compounds- Pregnant or breast feeding- Of childbearing potential in whom pregnancy cannot be excluded by a negative pregnancy test and who are not using reliable barrier method of contraception - Received an investigational drug in the past 30 days- Unable to take oral medication- Known to have congenital or sporadic syndromes of QTc prolongation or receiving concomitant medication reported to increase the QTc interval (e.g. amiodarone, sotalol, disopyramide, quinidine, procainamide, terfenadine) - End stage liver cirrhosis (class Child-Pugh C)- Severe renal impairment requiring dialysis - Previous history of tendinopathy associated with quinolones- Any symptoms that suggest that the patient's current illness is allergic rhinitis (e.g., repetitive sneezing, itchy nose or eyes, provocation by an allergen) and not acute bacterial sinusitis - Diagnosis of rapidly fatal illness with a life expectance of less than 6 months- Previously enrolled in this clinical study- Uncorrected hypokalaemia |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bayer |
United States, Argentina,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to bacteriological eradication in those who are microbiologically valid for S. pneumoniae, M. catarrhalis, and H. influenzae | Days 1, 2, 3 of treatment | No | |
Secondary | Patient-reported symptom improvement using SNOT-16 questionnaire | Up to End of Treatment (Day 10-13) | No | |
Secondary | Clinical Response | End of Treatment | Yes | |
Secondary | Bacteriological Response | End of Treatment | No | |
Secondary | Activity Impairment Assessment questionnaire | Up to End of Treatment (Day 10-13) | No | |
Secondary | Incidence of Premature Termination | Premature Termination | Yes | |
Secondary | Adverse Events Collection | Up to End of Treatment (Day 10-13) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04903418 -
Assessment of Relationship Between Maxillary Sinus Floor and Maxillary Posterior Teeth Root Tips Position
|
||
Completed |
NCT00683371 -
Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis
|
N/A | |
Completed |
NCT00236652 -
A Study Evaluating the Safety and Efficacy of Treating Sinus Infection With Levofloxacin 750 mg for 5 Days.
|
Phase 3 | |
Recruiting |
NCT06130176 -
Single-step Functional Sinus Endoscopy and Transoral Surgery
|
N/A | |
Recruiting |
NCT04241016 -
Endoscopic Sinus Surgery in Recurrent Acute Rhinosinusitis
|
N/A | |
Not yet recruiting |
NCT03083392 -
Endosseous Oroantral Port for Minimal Intervention in Treating Chronic Sinusitis
|
N/A | |
Recruiting |
NCT04645511 -
Balloon Sinuplasty Efficiency in Maxillary Rhinosinusitis.
|
N/A | |
Not yet recruiting |
NCT02931604 -
Study Designed to Clinically Evaluate Sinus Wash Device Prototypes
|
N/A | |
Completed |
NCT00643409 -
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults
|
Phase 3 | |
Terminated |
NCT00245440 -
Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis
|
Phase 4 | |
Completed |
NCT00537563 -
AMS VS MOXI Ketek vs Avelox in AMS
|
Phase 3 | |
Completed |
NCT00249210 -
A Study of the Safety and Effectiveness of Levofloxacin Compared With Amoxicillin/Clavulanate Potassium in the Treatment of Adults With Rapid Onset of Severe Inflammation/Infection of the Sinuses
|
Phase 3 | |
Completed |
NCT01032174 -
Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis
|
N/A |